Literature DB >> 33487126

Brain Magnetic Resonance Imaging Volumetric Measures of Functional Outcome after Severe Traumatic Brain Injury in Adolescents.

Peter Ferrazzano1,2, Benjamin Yeske1, Jeanette Mumford3, Gregory Kirk1, Erin D Bigler4,5,6, Katherine Bowen7, Nicole O'Brien8, Bedda Rosario9, Sue R Beers10, Paul Rathouz11, Michael J Bell12, Andrew L Alexander1,13,14,15.   

Abstract

Adolescent traumatic brain injury (TBI) is a major public health concern, resulting in >35,000 hospitalizations in the United States each year. Although neuroimaging is a primary diagnostic tool in the clinical assessment of TBI, our understanding of how specific neuroimaging findings relate to outcome remains limited. Our study aims to identify imaging biomarkers of long-term neurocognitive outcome after severe adolescent TBI. Twenty-four adolescents with severe TBI (Glasgow Coma Scale ≤8) enrolled in the ADAPT (Approaches and Decisions after Pediatric TBI) study were recruited for magnetic resonance imaging (MRI) scanning 1-2 years post-injury at 13 participating sites. Subjects underwent outcome assessments ∼1-year post-injury, including the Wechsler Abbreviated Scale of Intelligence (IQ) and the Pediatric Glasgow Outcome Scale-Extended (GOSE-Peds). A typically developing control cohort of 38 age-matched adolescents also underwent scanning and neurocognitive assessment. Brain-image segmentation was performed on T1-weighted images using Freesurfer. Brain and ventricular cerebrospinal fluid volumes were used to compute a ventricle-to-brain ratio (VBR) for each subject, and the corpus callosum cross-sectional area was determined in the midline for each subject. The TBI group demonstrated higher VBR and lower corpus callosum area compared to the control cohort. After adjusting for age and sex, VBR was significantly related with GOSE-Peds score in the TBI group (n = 24, p = 0.01, cumulative odds ratio = 2.18). After adjusting for age, sex, intracranial volume, and brain volume, corpus callosum cross-sectional area correlated significantly with IQ score in the TBI group (partial cor = 0.68, n = 18, p = 0.007) and with PSI (partial cor = 0.33, p = 0.02). No association was found between VBR and IQ or between corpus callosum and GOSE-Peds. After severe adolescent TBI, quantitative MRI measures of VBR and corpus callosum cross-sectional area are associated with global functional outcome and neurocognitive outcomes, respectively.

Entities:  

Keywords:  MRI; cognitive function; corpus callosum; severe adolescent brain injury; traumatic brain injury; ventricle-to-brain ratio

Mesh:

Year:  2021        PMID: 33487126      PMCID: PMC8219192          DOI: 10.1089/neu.2019.6918

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   4.869


  87 in total

1.  Cortical surface-based analysis. I. Segmentation and surface reconstruction.

Authors:  A M Dale; B Fischl; M I Sereno
Journal:  Neuroimage       Date:  1999-02       Impact factor: 6.556

2.  MR imaging of the corpus callosum in pediatric patients with neurofibromatosis type 1.

Authors:  E C Dubovsky; T N Booth; G Vezina; C A Samango-Sprouse; K M Palmer; C O Brasseux
Journal:  AJNR Am J Neuroradiol       Date:  2001-01       Impact factor: 3.825

3.  Normal postnatal development of the corpus callosum as demonstrated by MR imaging.

Authors:  A J Barkovich; B O Kjos
Journal:  AJNR Am J Neuroradiol       Date:  1988 May-Jun       Impact factor: 3.825

4.  Quantitative analysis of the corpus callosum in children with cerebral palsy and developmental delay: correlation with cerebral white matter volume.

Authors:  Ashok Panigrahy; Patrick D Barnes; Robert L Robertson; Lynn A Sleeper; James W Sayre
Journal:  Pediatr Radiol       Date:  2005-09-01

5.  Correlation of atrophy measures on MRI with neuropsychological sequelae in children and adolescents with traumatic brain injury.

Authors:  K Verger; C Junqué; H S Levin; M A Jurado; M Pérez-Gómez; D Bartrés-Faz; M Barrios; A Alvarez; F Bartumeus; J M Mercader
Journal:  Brain Inj       Date:  2001-03       Impact factor: 2.311

6.  Hippocampus, amygdala and global brain changes 10 years after childhood traumatic brain injury.

Authors:  M H Beauchamp; M Ditchfield; J J Maller; C Catroppa; C Godfrey; J V Rosenfeld; M J Kean; V A Anderson
Journal:  Int J Dev Neurosci       Date:  2010-12-13       Impact factor: 2.457

7.  Validity of a pediatric version of the Glasgow Outcome Scale-Extended.

Authors:  Sue R Beers; Stephen R Wisniewski; Pamela Garcia-Filion; Ye Tian; Thomas Hahner; Rachel P Berger; Michael J Bell; P David Adelson
Journal:  J Neurotrauma       Date:  2012-04-10       Impact factor: 5.269

8.  Longitudinal changes in patients with traumatic brain injury assessed with diffusion-tensor and volumetric imaging.

Authors:  Barbara B Bendlin; Michele L Ries; Mariana Lazar; Andrew L Alexander; Robert J Dempsey; Howard A Rowley; Jack E Sherman; Sterling C Johnson
Journal:  Neuroimage       Date:  2008-05-07       Impact factor: 6.556

9.  Magnetic resonance spectroscopy of fiber tracts in children with traumatic brain injury: A combined MRS - Diffusion MRI study.

Authors:  Emily L Dennis; Talin Babikian; Jeffry Alger; Faisal Rashid; Julio E Villalon-Reina; Yan Jin; Alexander Olsen; Richard Mink; Christopher Babbitt; Jeffrey Johnson; Christopher C Giza; Paul M Thompson; Robert F Asarnow
Journal:  Hum Brain Mapp       Date:  2018-05-10       Impact factor: 5.038

10.  Traumatic brain injury, neuroimaging, and neurodegeneration.

Authors:  Erin D Bigler
Journal:  Front Hum Neurosci       Date:  2013-08-06       Impact factor: 3.169

View more
  1 in total

1.  Genetic inactivation of SARM1 axon degeneration pathway improves outcome trajectory after experimental traumatic brain injury based on pathological, radiological, and functional measures.

Authors:  Donald V Bradshaw; Andrew K Knutsen; Alexandru Korotcov; Genevieve M Sullivan; Kryslaine L Radomski; Bernard J Dardzinski; Xiaomei Zi; Dennis P McDaniel; Regina C Armstrong
Journal:  Acta Neuropathol Commun       Date:  2021-05-17       Impact factor: 7.801

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.